Discovery of BMS-986144, a Third-Generation, Pan-Genotype NS3/4A Protease Inhibitor for the Treatment of Hepatitis C Virus Infection-Reference-Cited by-同舟云学术

Discovery of BMS-986144, a Third-Generation, Pan-Genotype NS3/4A Protease Inhibitor for the Treatment of Hepatitis C Virus Infection

Published:2020-11-23 Issue:23 Volume:63 Page:14740-14760
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Sun Li-Qiang¹^ORCID,Mull Eric²,D’Andrea Stanley²,Zheng Barbara¹^ORCID,Hiebert Sheldon²,Gillis Eric²,Bowsher Michael²,Kandhasamy Sarkunam³,Baratam Venkata Rao³,Puttaswamy Sunitha³,Pulicharla Nagalakshmi³,Vishwakrishnan Sureshbabu³,Reddy Subba³,Trivedi Ravi³,Sinha Sarmistha³,Sivaprasad Sankar³,Rao Abhijith³,Desai Salil³,Ghosh Kaushik³^ORCID,Anumula Rushith³,Kumar Amit³,Rajamani Ramkumar⁴,Wang Ying-Kai¹,Fang Hua²,Mathur Arvind²,Rampulla Richard²,Zvyaga Tatyana A.²,Mosure Kathy⁴,Jenkins Susan²,Falk Paul²,Tagore Debarati M.³,Chen Chaoqun²,Rendunchintala Kishore³,Loy James⁴,Meanwell Nicholas A.¹^ORCID,McPhee Fiona⁴,Scola Paul M.⁴

Affiliation:

1. Bristol Myers Squibb Research and Early Development, Route 206 & Province Line Road, Princeton, New Jersey 08543, United States

2. Bristol Myers Squibb Research and Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States

3. Biocon-Bristol Myers Squibb Research and Development Center, Biocon Park, Bommasandra IV Phase, Jigani Link Road, Bangalore 560099, India

4. Bristol Myers Squibb Research and Early Development, 100 Binney Street, Cambridge, Massachusetts 02142, United States

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.0c01296

Reference39 articles.

1. Challenges and perspectives of direct antivirals for the treatment of hepatitis C virus infection

2. HCV: The Journey from Discovery to a Cure;Wang G.,2020

3. Discovery of the pan-genotypic hepatitis C virus NS3/4A protease inhibitor voxilaprevir (GS-9857): A component of Vosevi®

4. Discovery of MK-5172, a Macrocyclic Hepatitis C Virus NS3/4a Protease Inhibitor

5. Unraveling the structural basis of grazoprevir potency against clinically relevant substitutions in hepatitis C virus NS3/4A protease from genotype 1a

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Missing Link(er): A Roadmap to Macrocyclization in Drug Discovery;Journal of Medicinal Chemistry;2024-08-22

2. Macrocyclization strategy for improving candidate profiles in medicinal chemistry;European Journal of Medicinal Chemistry;2024-06

3. Hepatitis C: The Story of a Long Journey through First, Second, and Third Generation NS3/4A Peptidomimetic Inhibitors. What Did We Learn?;Journal of Medicinal Chemistry;2024-01-05

4. The Magic Methyl and Its Tricks in Drug Discovery and Development;Pharmaceuticals;2023-08-15

5. Deuterium in drug discovery: progress, opportunities and challenges;Nature Reviews Drug Discovery;2023-06-05